Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jarret Helstern

Nurse Practitioner, Family Skokie, IL Nurse Practitioner

NPI 1992169015 CMS profile 11253422

4711 Golf Rd, Suite 1200, Skokie, IL 60076

Open in the dashboard

General payments

$109,881

1,028 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jarret Helstern of Skokie, IL is reported in the CMS Open Payments database as having received $109,881 across 1,028 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,255 224
2024 General $51,791 301
2023 General $33,679 236
2022 General $9,729 130
2021 General $3,428 137

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jarret Helstern
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jarret Helstern were reported at $11,255. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jarret Helstern Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $3,428 $124 $35–$379 $132
2022 $9,729 $141 $44–$430 $149
2023 $33,679 $154 $49–$476 $160
2024 $51,791 $165 $51–$504 $164
2025 $11,255 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Otsuka America Pharmaceutical, Inc. $53,110 150 payments
  2. AbbVie, Inc. $42,720 289 payments
  3. ITI, Inc. $2,377 69 payments
  4. Neurocrine Biosciences, Inc. $1,740 42 payments
  5. Lundbeck LLC $1,379 87 payments
  6. Supernus Pharmaceuticals, Inc. $1,177 86 payments
  7. Alkermes, Inc. $993 30 payments
  8. Axsome Therapeutics, Inc. $666 36 payments
  9. Corium, Inc. $549 25 payments
  10. Janssen Pharmaceuticals, Inc $491 20 payments
  11. Other $4,678 194 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $77,481 61 payments
  2. Food and Beverage $20,762 864 payments
  3. Travel and Lodging $10,092 75 payments
  4. Consulting Fee $1,353 2 payments
  5. Education $194 26 payments
Products named General payments · program years 2021–2025
  1. REXULTI Psychiatry $53,042 155 payments
  2. VRAYLAR Neuroscience $39,094 227 payments
  3. VRAYLAR Neuroscience $3,281 52 payments
  4. CAPLYTA $1,837 48 payments
  5. INGREZZA $1,314 33 payments
  6. REXULTI Psychiatry $917 60 payments
  7. LYBALVI $827 26 payments
  8. QELBREE $599 55 payments
  9. ARISTADA Cns $581 24 payments
  10. ARISTADA Cns $581 24 payments
  11. Other $11,852 463 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

1,385

Median for Nurse Practitioner: 389

Drug cost

$358,569

Median for Nurse Practitioner: $21,885

Branded share of claims

28.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Spravato Esketamine Hcl Brand 32 $154,478
Vraylar Cariprazine Hcl Brand 24 $37,493
Invega Sustenna Paliperidone Palmitate Brand 12 $32,342
Ozempic Semaglutide Brand 28 $30,782
Rexulti Brexpiprazole Brand 12 $26,115
Mounjaro Tirzepatide Brand 21 $21,455
Lurasidone Hcl Generic 19 $12,631
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 46 $6,972
Lisdexamfetamine Dimesylate Generic 29 $6,371
Quviviq Daridorexant Hcl Brand 11 $5,168

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$11,912

Medicare's payments for the services billed

Medicare patients

32

Average age 64

Services billed

185

13 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 53%
High blood pressure 50%
Arthritis 50%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
$40,710 12 —
VRAYLAR
$7,742 24 —
CAPLYTA
$897 — —
INGREZZA
$363 — —
Qelbree
$356 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

1,028 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record